Locally Advanced Or Metastatic Ros1 Positive Non Small Cell Lung Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for locally advanced or metastatic ros1 positive non small cell lung cancer. 10 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
10
Active US patents
47/100
Avg vulnerability
$200M
Annual revenue covered

Originators in Locally Advanced Or Metastatic Ros1 Positive Non Small Cell Lung Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol 10 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating locally advanced or metastatic ros1 positive non small cell lung cancer. Each bar = one year. Y-axis scaled to peak year (8 patents).

2
35
8
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Augtyro
REPOTRECTINIB
 Bristol 10 47 $200M 2035-01-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12310968 Augtyro method of use 75 2036-07-20
12310968 Augtyro method of use 75 2036-07-20
11452725 Augtyro method of use 75 2036-07-24
11452725 Augtyro method of use 70 2036-07-24
12187739 Augtyro formulation 55 2036-07-05
12187739 Augtyro formulation 55 2036-07-05
RE50634 Augtyro composition of matter 17 2035-01-23
RE50634 Augtyro composition of matter 17 2035-01-23
10294242 Augtyro composition of matter 17 2036-07-05
10294242 Augtyro composition of matter 12 2036-07-05

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10294242 Augtyro composition of matter 12 2036-07-05
10294242 Augtyro composition of matter 17 2036-07-05
RE50634 Augtyro composition of matter 17 2035-01-23
RE50634 Augtyro composition of matter 17 2035-01-23
12187739 Augtyro formulation 55 2036-07-05
12187739 Augtyro formulation 55 2036-07-05
11452725 Augtyro method of use 70 2036-07-24
11452725 Augtyro method of use 75 2036-07-24
12310968 Augtyro method of use 75 2036-07-20
12310968 Augtyro method of use 75 2036-07-20

Related